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Small Bowel and Liver/Small Bowel Transplantation in Children 
By Jorge Reyes, Andreas G. Tzakis, pat~ru Todo, Bakr Nour, and Thomas E. Starzl 
Pittsburgh, Pennsylvania 
A clinical trial of intestinal transplantation was initiated at 
the University of Pittsburgh in May 1990. Eleven children 
received either a combined liver / small bowel graft (n = 8) or 
an isolated small bowel graft (n = 3). Induction as well as 
maintenance immunosuppression was with FK-506 and ste-
roids. Four patients were male, and seven were female; the 
age range was 6 months to 10.2 years. There were 3 deaths 
(all in recipients of the combined liver/small bowel graft). 
which were attributed to graft-versus-host disease (n = 1), 
posttransplant Iymphoproliferative disease (n = 1), and bili-
ary leak (n = 1). Transplantation of the intestine has evolved 
into a feasible operation, with an overall patient and graft 
survival rate of 73%. These survivors are free of total 
parenteral nutrition, and the majority are home. These encour-
aging results justify further clinical trials. 
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THE OUTLOOK for patients with intestinal fail-
ure has changed dramatically over the last 20 
years. Many physicians involved in the care of infant 
patients who required extensive resections of the 
intestine can recall when survival was considered at 
best "unlikely." Survival was usually limited to pa-
tients who had the opportunity to undergo some 
adaptation of the remaining bowel. Advances in 
preoperative and postoperative management to-
gether with the development of total parenteral 
nutrition (TPN) have been responsible for this im-
provement during the acute stage of disease. The 
long-term prognosis for these patients varies from 
65% to 80% (3-year survival) depending on the cause 
of intestinal failure.' This may be less favorable in 
children as compared with adults because of a higher 
risk for TPN-induced liver dysfunction and venous 
access complications. The availability of home TPN 
has further simplified the management, although 
there are still significant limitations on function as 
individuals and in society. The expense of such 
lifetime therapy is estimated at $60,000 to $150,000 
per year. 
The technical feasibility of intestinal transplanta-
tion was pioneered in 1959 by the experimental model 
of Lillehei et al,2.3 who studied both autografts and 
allografts in dogs. Transplantation of the small intes-
tine as part of a multivisceral graft was reported 
experimentally 1 year later by Starzl and Kaupp at the 
American Surgical Association meeting.4 This was 
only 1 year after experimental liver transplantation 
was performed in Chicago and Boston. Numerous 
attempts at clinical small intestinal transplantation, 
either alone or with the liver, were attempted be-
tween 1964 and 1987.5 Almost all attempts have failed 
Seminars in Pediatric Surgery, Vo12, No 4 (November), 1993: pp 289-300 
from either graft rejection, sepsis, or technical failure, 
with loss of graft and, many times, of the patient. 
Until 1990, there were only two survivors of isolated 
cadaveric grafts, one in France and the other in 
Germany.6,7 
A trial of small bowel transplantation alone or with 
the liver was initiated at the University of Pittsburgh 
in 1990 in both adults and children.s The longest-
surviving child of this series, the recipient of a 
combined liver-intestinal graft more than 2 years 
ago, 8 has enjoyed a normal life-style free of TPN for 
essentially all of her posttransplant life.9 Although 
the present success of intestinal transplantation un-
der FK-506 has been met with enthusiasm, the 
procedure and postoperative course is complex. 
INDICATIONS 
Small bowel transplantation is indicated in any 
patient with permanent intestinal failure who is 
dependent on TPN for maintenance of nutrition, 
fluid and electrolyte balance, and normal growth and 
development. There are many disease states that 
produce intestinal failure for varying lengths of time. 
Also, adaptation of the intestine permits recovery in 
many patients after a period of temporary TPN 
support. The small number of patients with perma-
nent intestinal failure can go on to have complications 
related to the long-term use of TPN (eg, catheter 
infections and venous thrombosis). Multiple hospital 
admissions are usually required for intravenous (IV) 
antibiotic therapy and catheter changes. In some 
patients, thrombosis is so extensive that venous access 
becomes impossible. Also, TPN-induced liver dysfunc-
tion can occur and is manifested by abnormalities in 
liver chemistries, hepatic cholcstasis, steatosis, and 
eventually cirrhosis with liver failure. lO 
The minimum length of intestine necessary for 
adequate enteral absorption has not been estab-
lished. Various investigators advocate anywhere be-
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tween 10 and 20 em of small intestine with an 
ileocecal valve, and 40 em without one. 11,12 Other 
factors that influence use of the remaining small 
bowel include the presence of residual ileum (be-
cause of its greater potential for adaptation), ileoce-
cal valve (slowing of intestinal transit time), presence 
of the colon (water absorption), and motility patterns 
as well as improvement of absorptive function of the 
remaining intestine. 
Table 1 lists the indications for liver/small bowel 
and isolated small bowel transplantation in 11 chil-
dren who received transplants between May 1990 and 
June 1992. The causes of intestinal failure in this 
group can be divided into two categories: surgical and 
nonsurgical. Patients with surgical causes are those 
who present with a small length of bowel after 
resection for intestinal atresias, or infarctions conse-
quent to volvulus, necrotizing enterocolitis, vascular 
catastrophes (trauma or thrombosis), and gastroschi-
sis. The length of residual intestine present has been 
variable. Nonsurgical causes of intestinal failure in-
clude motility disorders such as intestinal pseudoob-
struction syndromes and absorptive insufficiency as is 
seen in microvillus inclusion disease. 
Patients presenting with TPN-induced liver disease 
are candidates for liver/small bowel transplantation. 
The severity of the liver disease will stipulate the need 
for a concomitant liver transplant; however, this is not 
always a straightforward decision. Hyperbilirubine-
mia and transaminase abnormalities are insensitive 
guidelines. The presence of fibrosis (or cirrhosis) on 
liver biopsy, or portal hypertension as manifested by 
splenomegaly and esophageal varices, are already 
late manifestations of severe hepatic injury. Choosing 
the optimum time for transplantation in this type of 
patient is difficult because the clinical course and life 
expectancy are variable. The patients are highly 
susceptible to sudden unpredictable deterioration 
such as bleeding, sepsis, and encephalopathy. 
EVALUATION OF CANDIDATES 
There is no test more critical in the preoperative 
evaluation of a potential small bowel transplant 
Table 1. Indications for Pediatric Small Bowel Transplantation 
Necrotizing enterocolitis 
Gastroschisis 
Intestinal atresia 
Midgut volvulus 
Intestinal pseudoobstruction 
Microvillous inclusion disease 
Total 
No. of 
Patients 
3 
2 
3 
11 
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recipient than a thorough history and physical exami-
nation. It is necessary to have a complete understand-
ing of the cause of intestinal failure (surgical or 
nonsurgical) as well as possible associated defects in 
other organ systems. 
Knowledge of all previous operative procedures 
and present intestinal tract anatomy is critical to the 
accomplishment of a smooth operative procedure. 
Also, segments of the remaining intestinal tract may 
be significantly deformed or functionally inadequate 
because of either previous surgery or baseline pathol-
ogy (nonsurgical intestinal failure). This evaluation 
can be accomplished with standard barium studies of 
the gastrointestinal tract, motility studies, and absorp-
tion studies when appropriate. 
Evaluation of hepatic integrity is by standard liver 
transplant evaluation protocol. Jaundice, which may 
or may not be present, is not a sensitive indicator in 
assessing critical liver injury. Tests for hepatocellular 
reserve using a coagulation profile, albumin level, and 
ammonia level are standard practice in liver trans-
plant centers around the world. Evidence of portal 
hypertension includes a history of bleeding esopha-
geal varices, the presence of splenomegaly, ascites, 
and caput medusae. Diagnostic upper gastrointesti-
nal endoscopy, if not previously performed, can be 
useful, and it can be performed therapeutically if the 
patient has an episode of bleeding while under 
evaluation. Bleeding esophageal varices are treated 
with sclerotherapy. 
Patency of the portal vein is required to assess for 
adequate drainage of the visceral organs that will 
remain in the recipient after transplantation (usually 
the stomach, duodenum, pancreas, and possibly the 
colon). Patency is documented by Doppler ultra-
sound. If occlusion is found, it should be confirmed by 
magnetic resonance imaging or venous phase portog-
raphy. Occlusion of the portal vein does not contrain-
dicate transplantation because in this instance a 
multivisceral transplant can be performed after all 
the native intraabdominal organs are excised. 
Nutritional evaluation consists of a thorough his-
tory focusing on the present TPN formula and any 
type of oral diet or supplementation. Tolerance to 
oral intake is crucial (eating profile and stool output) 
because many children have not learned or have 
forgotten to eat. Some patients associate adverse 
feelings with eating. This can affect posttransplant 
nutritional management by delaying independence 
from enteral formula support. Children should be 
stimulated to eat before transplant, even if no nutri-
tional benefit is gained. Baseline anthropometric 
measurements as well as laboratory data are col-
lected. Most patients with only intestinal failure are 
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in good overall medical condition and sufler more 
from recurrent line sepsis and vessel thrombosis. 
However, patients presenting with liver and intestinal 
failure may have significant immunologic defects as 
well as nutritional deficiencies (principally vitamins 
and trace elements), fluid and electrolyte imbalances, 
and often obesity. They may present a cushingoid 
appearance and are susceptible to serious infections, 
bleeding, and encephalopathy. 
All patients are screened with baseline titers for 
cytomegalovirus (CMV) and Epstein-Barr virus 
(EBV). Bacterial, fungal, and viral cultures are ob-
tained when clinically indicated. A thorough history 
of previous infectious complications is critical, particu-
larly if there has been an episode of fungal infection. 
Table 2 outlines our present protocol for intestinal 
transplant evaluation. 
THE DONOR OPERATION 
Donors who are suitable for liver donation should 
also be suitable for small intestinal donation. No 
Table 2. Investigation of Pediatric Small Bowel Transplant 
Recipients 
History and physical examination 
Etiology of intestinal failure 
Previous surgeries 
Associated anomalies 
Routine laboratory data 
Hemoglobin, leukocyte count, differential count 
Platelet count, prothrombin time, partial thromboplastin time 
Bilirubin, alkaline phosphatase, serum glutamic-pyruvic trans-
aminase (SGPT), aspartate aminotransferase (AST) 
Protein electrophoresis 
a-fetoprotein 
Urinalysis 
Blood urea nitrogen (BUN), serum creatinine 
24-hour creatinine clearance 
Nutritional evaluation 
Weight, height, triceps skinfold, midarm circumference 
Transferrin, albumin, prealbumin, serum amino acid analysis 
Vitamins A, D, E, 8'2' thiamine 
Triglycerides 
Radiology 
Upper and lower gastrointestinal barium studies 
Liver ultrasound 
Chest roentgenogram 
Immunological studies 
Blood type (ABO) 
Tissue typing 
Cross matching 
Investigations for infection 
Blood, urine, throat, feces, ascites culture: bacterial, fungal, viral 
Hepatitis screen 
Quantitative stool cultures 
Absorption studies (when indicated) 
D-Xylose absorption test 
72-hour fecal fat test 
Liver biopsy (when indicated) 
Table 3. Intestinal Decontamination-Donor and Recipient 
<5 51012 
Years Years 
Amphotericin B (mg) 100 250 
Tobramycin (mg) 10 40 
Polymycin E (mg) 25 50 
Systemic Antibiotics 
Cefotaxime 25 mg/kg/dose every 8 h IV 
Ampicilin 25 mg/kg/dose every 6 h IV 
>12 
Years 
500 
80 
100 
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functional or anatomic assessment of the intestine is 
performed. We select a donor who is of similar or 
smaller size than the recipient because the volume of 
the peritoneal cavity in the recipient is usually re-
duced. The ABO blood group should be identical to 
that of the recipient; the human lymphocyte antigen 
(HLA) matching is random. Selective bacterial and 
fungal decontamination is performed in the donor 
according to the outline in Table 3. No attempt is 
made to mechanically wash the intestinal contents 
either before the donor operation or after the organs 
have been transplanted. 
An isolated small bowel or en-bloc liver/small 
bowel graft usually requires approximately 4 hours of 
recovery time. The harvesting technique involves a 
hilar dissection similar to that performed in an 
isolated liver graft. 13 The ascending and transverse 
colon are mobilized, and the small intestine is divided 
with a stapler at the ligament of Treitz and just 
proximal to the ileocecal valve, leaving the enteric 
contents undisturbed. A duodenopancreatectomy ex-
poses the portal and superior mesenteric veins. The 
aorta is encircled below the diaphragm for later 
cross-clamping when the circulation is arrested. The 
distal infrarenal aorta is also encircled, and a cannula 
is inserted at this point for the infusion of the 
preservation fluid. After the proximal aorta is clamped, 
in situ arterial perfusion is initiated using chilled 
University of Wisconsin (UW) solution, and the 
venous bed is decompressed via a suprahepatic vena 
caval venotomy. The amount of fluid volume infused 
is variable and should be guided by blanching of the 
organs. Because the volume for the non hepatic vis-
cera is usually less, the liver can be perfused more 
thoroughly by cannulation of the inferior mesenteric 
vein or the splenic vein14 (Fig 1). Alteration of the 
graft lymphoreticular tissue (with the use of antilym-
phocyte globulin [ALG], OKT3, or irradiation) is not 
performed. is The liver and small bowel from the 
ligament of Treitz to the ileocecal valve are harvested 
en-bloc and used for liver/small bowel candidates. 
For cases in which only a small bowel graft is 
required, the graft can be separated on the back table 
and the liver used for another recipient. 
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Fi9 1. Procurement of multivisceral graft. Inset shows secondary 
perfusion of the liver through inferior mesenteric vein (IMV). PV, 
portal vein; SMV, superior mesenteric vein. (By permission of SUR-
GERY. Gynecology & Obstetrics. 14) 
THE RECIPIENT OPERATION 
The recipient is brought to the operating room 
once news from the donor team confirms adequacy of 
the donor organs. Because the graft is generally 
brought en-bloc either as a multivisceral or a liver / 
small bowel graft, the final decision regarding the 
patient's organ needs can be made at the time of 
exploration. Patients presenting with jaundice and 
biopsy-confirmed cirrhosis, or severe fibrosis and 
cholestatic liver disease in which significant portal 
hypertension is confirmed at exploration, will receive 
an en-bloc liver/small bowel graft. Patients who do 
not present the above findings and have only chemical 
abnormalities (noted on liver-function tests) with no 
evidence of portal hypertension usually require an 
isolated small bowel graft only. 
When an en-bloc liver/small bowel graft is trans-
planted, the abdomen is entered through previous 
incisions, and after takedown of adhesions the he-
patic hilus is exposed. The liver is devascularized by 
ligating the hepatic arterial branches and the com-
mon bile duct, thus exposing the portal vein from the 
confluence to its bifurcation. Subsequently the portal 
vein is tied and sectioned, and the liver is removed in 
a piggyback fashion by sequentially ligating the veins 
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draining directly into the retrohepatic inferior vena 
cava and then clamping the hepatic veins and remov-
ing the liver (Fig 2). A temporary portocaval shunt is 
used to allow decompression of the remaining splanch-
nic organs (stomach, duodenum, pancreas, and 
spleen).16 The amount of residual intestine varies 
from very little in patients who have had previous 
resections to the entire intestine in those who present 
with malabsorption or pseudoobstruction. We always 
attempt to preserve the colon and ileocecal valve. 
Any residual small intestine found is preserved; in 
patients with malabsorption or intestinal pseudoob-
struction, the small intestine and colon are removed. 
After hemostasis is accomplished. the liver/small 
bowel graft is brought to the operative field. The 
small bowel graft, with or without the liver, encom-
passes its entire length. The exact method of revascu-
larization depends on the operative findings of the 
recipient, which can be distorted by multiple previous 
abdominal procedures. When the liver is removed in 
a piggyback fashion. the venous drainage is into the 
Fig 2. Recipient. The liver has been removed and a portocaval 
shunt performed. This relieves the portal hypertension and permits 
completion of hemostasis. The shunt may be left permanently, or 
taken down and a native porto-to-donor portal shunt performed. 
(Reprinted with permission.") 
----_._------_._----------
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hepatic veins of the recipient. If the retrohepatic vena 
cava of the host is removed with the specimen, then 
this segment of vena cava is replaced with the graft 
(Fig 3). In this situation the use of veno-venous 
bypass is necessary to channel blood from the splanch-
nic system and lower body back to the heart. 17 
Arterialization is performed using a carrel patch of 
the donor aorta, which includes celiac and superior 
mesenteric arteries. This is anastomosed directly to 
the recipient aorta either above or below the renal 
arteries. An interposition graft of donor thoracic or 
abdominal aorta can also be sutured to this carrel 
patch, then subsequently to the recipient aorta. When 
the small intestine is transplanted alone, it is based on 
the superior mesenteric artery (with or without an 
aortic carrel patch) and a skeletonized segment of 
superior mesenteric vein or portal vein. Arterializa-
tion is from the recipient infrarenal aorta.8 Venous 
drainage has usually been accomplished either di-
rectly to the stump of remaining recipient superior 
mesenteric vein or to the recipient's portal vein at the 
level of the hepatic hilus in an end-to-side fashion 
o Retained organs 
ED Donor organs 
Fig 3. Venous drainage of the combined graft without and with 
(inset) preservation of the inferior vena cava (IVC). Inset also shows 
native porto-to-donor portal shunt. PV, portal vein. (By permission of 
SURGERY, Gynecology & Obstetrics. 14) 
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Fig 4. Venous drainage of isolated small bowel graft into native 
superior mesenteric vein (SMV), portal vein (PV), or vena cava (VC). 
(Reprinted with permission.e) 
(piggyback technique ).18 Drainage into the inferior 
vena cava has been performed during retransplanta-
tion in an adult recipient of a small bowel graft only 
(Fig 4). 
After the vascular anastomosis is completed, blood 
is allowed to perfuse the organs; however, the venous 
drainage clamp is not released until the organs are 
completely perfused. Bleeding is allowed to occur 
from the superior mesenteric vein (in an isolated 
small bowel graft) or from the infrahepatic vena cava 
(in the liver/small bowel graft). This permits drainage 
of the preservation solutions. After the subsequent 
removal of the venous drainage clamp, there may be 
some peaked T waves that can usually be easily 
treated with intravenous calcium and bicarbonate 
solutions. Once hemostasis is achieved, a donor 
cholestectomy is performed, and reconstruction of 
the gastrointestinal tract is accomplished with a 
conventional technique. In the initial two cases, both 
ends of the intestinal graft were exteriorized by a 
"chimney" method anastomosing the recipient intes-
tines to the side of the graft near the chimney 
enterostomy.9 In the subsequent cases the proximal 
chimney was eliminated, and a tube jejunostomy was 
used to drain the proximal intestine. This tube is 
subsequently used for enteral nutrition. The biliary 
reconstruction is required only in liver/small bowel 
recipients and is performed with a Roux-en-Y cho-
ledochojejunostomy at the most proximal end of the 
transplanted jejunum (Fig 5). 
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Fig 5. Composite graft showing biliary reconstruction to the most 
proximal end of transplanted jejunum, proximal enteric anastomosis, 
jejunostomy drainage tube, and then distal enteric anastomosis. 
(Reprinted with permission.·) 
IMMUNOSUPPRESSION 
The prospects for progress in intestinal grafting 
have improved dramatically with the use of FK-S06 
immunosuppression. To avoid nephrotoxic levels, 
FK-S06 (0.1 to O.lS mg/kg/ d) is given by continuous 
intravenous (IV) infusion immediately after graft 
revascularization. Steady levels are targeted at be-
tween 1 and 2 ng/mL. Levels are measured daily until 
discharge and then subsequently 2 to 3 times per 
week for the first 3 months and at longer intervals 
thereafter. Oral FK-S06 is started once intestinal 
motility is present, and integrity of the intestinal 
anastomosis is confirmed by contrast barium studies. 
Because FK-S06 absorption is independent of biliary 
enterohepatic circulation,19 maintenance of adequate 
levels by oral dosage alone is possible early in the 
postoperative course. Steroid therapy in the isolated 
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small bowel recipients consists of 1 g of IV hydrocor-
tisone given intraoperatively, followed by methylpred-
nisolone starting at a dose of 100 mg/d and then 
rapidly tapering over S days to a dose of 10 mg/ d. 
Recipients of liver/small bowel grafts received only 
baseline steroid therapy-20 mg/ d for patients weigh-
ing more than 10 kg, and 10 mg/d for patients 
weighing less than 10 kg. Prostaglandin E j is adminis-
tered at 0.003 to 0.009 fl-g/kg/ min intraoperatively 
and then continued for S days. This is given for its 
immunosuppressive properties and the beneficial ef-
fect seen with FK-S06 nephrotoxicity.20 
Episodes of graft rejection (liver and/or small 
bowel) are treated initially with steroid bolus therapy 
using IV hydrocortisone or oral prednisone. Optimi-
zation of FK-S06 trough levels should be performed 
by either increasing the baseline oral FK-S06 dose or 
using supplemental IV FK-S06. Rejection of the small 
bowel can alter FK-S06 absorption. Steroid recycle 
therapy (similar to induction tapering doses) is used 
in cases of more severe rejection or when bolus 
therapy is inadequate. Use of OKT3 was not required 
in any of these cases; however, it has been the next 
line of therapy in our adult small bowel recipients 
when rejection has progressed on a steroid recycle. 
Azathioprine was used to supplement baseline immu-
nosuppression in cases of severe rejection (two pa-
tients), and where reduction of the FK-S06 dose was 
necessary because of nephrotoxicity (two patients). 
Long-term immunosuppressive management has 
entailed reduction of FK-S06 dosage (independent of 
the level) if the patient is clinically well and has a 
normally functioning graft. At present, only two 
patients are using additional steroid and azathio-
prine. All other patients are on monotherapy with 
FK-506. 
INFECTION CONTROL 
All donors receive selective bacterial and fungal 
decontamination as outlined in Table 3. The number 
of doses given is variable and depends on the local 
organ procurement circumstances; however, an initial 
dose at the time of acceptance of the donor followed 
by a second dose just before transfer to the operating 
room is ideal. Mechanical preparation is not per-
formed. The recipient receives the same selective 
decontamination regimen. Because some candidates 
are hospitalized for varying periods before transplant, 
random screening of the intestinal flora should be 
performed and treated accordingly. Intestinal decon-
tamination is continued for a minimum of 6 weeks 
postoperatively and should be reinstituted during 
episodes of rejection. 
Broad-spectrum IV antibiotics (ampicillin and cefo-
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taxime) are administered to both donor and recipient. 
The recipient may have a history of nosocomial 
infections just before transplant (bacterial and fun-
gal), which need to be addressed appropriately. 
Prophylactic antibiotics are given for S days. 
POSTOPERATIVE CARE AND RESULTS 
Patients receiving a combined liver/small bowel 
graft usually have had significant liver failure and 
require the same level of intensive care as a liver-
transplant recipient. They require respiratory sup-
port for at least 48 hours, and are susceptible to 
significant fluid shifts. Accurate management of fluid 
and electrolytes is critical to avoid pulmonary edema 
or renal failure. Similarly, the management of FK-S06 
infusions and any antibiotic regimen requiring peak 
and trough levels (such as aminoglycosides and vanco-
mycin) should be meticulously gauged. 
Chest roentgenograms are checked daily while the 
patient is in the intensive-care unit, and when indi-
cated thereafter (eg, respiratory failure, fever workup, 
pneumonia). Daily determinations of renal function 
(blood urea nitrogen [BUN], creatinine), hematology 
(white blood cell count [WBC], platelets, hemoglobin 
levels), electrolytes, calcium, phosphate, magnesium, 
amylase, lipase, and hepatic function (bilirubin, trans-
aminase, and alkaline phosphatase levels) are per-
formed. 
Monitoring of the intestinal graft includes a combi-
nation of clinical, endoscopic, histological, radiologi-
cal, bacteriologic, and metabolic evaluations.l! The 
character of the intestinal graft stoma is assessed on a 
daily basis for color, friability, and stomal output 
(color, consistency, presence of blood, presence of 
reducing substances as tested by pH and clinitest). 
Endoscopic evaluation through the ileostomy with 
mucosal biopsies (minimum of five samples) is per-
formed twice a week for the first month and whenever 
clinically indicated thereafter. 
Most patients with intestinal allograft rejection 
presented a combination of fever, abdominal pain 
and distension, nausea or vomiting, and an initial 
increase in stomal output. In cases of severe rejection, 
graft ileus and absence of stomal output can occur, as 
well as intestinal bleeding from mucosal sloughing. A 
septic-shock picture can be seen with or without the 
presence of bacterial translocation (concomitant pres-
ence of thc same infectious organism in both blood 
and stool). This has been documented on mUltiple 
occasions and represents one of the few transplant 
situations in which treatment of sepsis entails not only 
antibiotic coverage but also, more importantly, addi-
tional immunosuppression. Intestinal decontamina-
tion should continue during episodes of rejection; 
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stomal cultures must be assessed for overgrowth 
(2: 108 is considered significant). 
Endoscopically acute rejection episodes are docu-
mented by an ischemic or dusky mucosa with focal 
ulcerations. A nodular mucosal pattern with diffuse 
ulcerations or sloughing of large areas of mucosa can 
be seen in cases of severe rejection (Fig 6A). Absence 
of peristalsis can be determined at endoscopy and 
confirmed by barium studies. 
The histological criteria for the diagnosis of acute 
intestinal allograft rejection include mononuclear cell 
infiltrates, villous blunting, and cryptitis. Complete 
mucosal and crypt destruction are seen in patients 
who have severe rejection (Fig 6B). The reader is 
referred to a more complete analysis of intestinal 
transplant pathology in this group of children and 
adults from this institution.22 
The results reported herein pertain to 11 children 
who received intestinal transplants. Eight transplants 
were in combination with the liver, and three were 
solitary. There were seven girls and four boys, with 
ages ranging from 6 months to 10 years. The specifics 
of these patients and their outcomes are detailed in 
Table 4. 
Two of the three patients who received small bowel 
grafts experienced at least one episode of rejection; 
one of these patients had only one rejection episode. 
The other had six episodes of rejection; however, all 
were treated successfully with bolus steroid therapy 
and optimization of FK-S06 trough levels. None of 
these episodes was severe. 
Of the eight liver/small bowel recipients, five 
patients experienced at least one episode of rejection 
of the intestinal graft (3.4 episodes per patient), and 
four patients had at least one episode of rejection of 
the liver graft (S.8 episodes per patient). Two patients 
had no episodes of rejection, and only one patient 
had two episodes of concomitant rejection of the liver 
and small bowel components of the graft. Of these 
patients, two had severe rejection of the intestinal 
graft with mucosal sloughing, requiring TPN support 
during treatment. The diagnosis and incidence of 
liver graft rejection in patients with a combined graft 
were similar to those experienced by a control group 
of recipients who received only a liver.23 No incidence 
of chronic rejection was seen in these pediatric 
patients; however, it has occurred in an adult recipi-
ent of an isolated small bowel graft. 
Patients who received the combined liver/small 
bowel transplant required a longer intensive care unit 
stay (mean, 37 days) than patients who received an 
isolated small bowel transplant (mean, 8 days) as well 
as a longer total hospital stay (mean, 4.S months 
versus mean, 2.3 months for an isolated small bowel 
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Table 4. Clinical Characteristics 
Age a! 
Patient Transplant 
No. (mo) Primary Disease 
38 Necrotizing enterocolitis 
2 52 Gastroschisis 
3 33 Necrotizing enterocolitis 
4 6 Intestinal atresia 
5 13 Midgut volvulus 
6 19 Midgut volvulus 
7 31 Microvillous inclusion 
8 14 Midgut volvulus 
9 123 Intestinal pseudo obstruction 
10 18 Necrotizing enterocolitis 
11 48 Gastroschisis 
Abbreviations: SB, small bowel; LSB, liver/small bowel. 
transplant). This can be explained by the fact that 
candidates for a liver/small bowel graft generally 
have end-stage liver disease with many of its associ-
ated complications. In addition, the procedure re-
quires significantly more operative time and blood 
transfusions. The incidence of infection and technical 
complications is also significantly higher. 
The only acceptable standard of success with intes-
tinal transplantation is independence from TPN. 
Therefore, the functional assessment of the trans-
planted small bowel is critical and can be divided into 
three phases. Phase 1 begins with perfusion of the 
intestinal graft and ends when initial stomal output 
occurs postoperatively (usually between days 5 and 
8). The intestinal graft usually perfuses rapidly; how-
ever, there may be segments of initial venous conges-
tion and spasm that require careful manipulation and 
positioning of the graft as well as irrigation with warm 
saline solutions. Peristalsis may be present; however, 
more often than not the intestine remains aperistal-
tic. This is reflected postoperatively by a significant 
period of ileus. Ischemic damage to the graft may 
occur during this time and be manifested by conges-
tion, edema, and aperistalsis. Mucosal sloughing and 
bleeding may also occur. Phase 2 encompasses the 
period when rejection episodes are most commonly 
encountered (after the first week) and treated in the 
manner as described in previous sections. Intestinal 
motility begins to recover at this time, and the passage 
of stool through the ileostomy signals the moment to 
begin enteral feeding. During phases 1 and 2, ad-
equacy of perfusion and control of rejection are the 
goals permitting recovery of the intestinal graft, and 
they are best reflected by the presence of peristalsis 
and stomal outputs. This can be confirmed by a 
gastrointestinal barium study showing adequacy of 
the intestinal anastomosis, peristalsis, and the con-
tour of the mucosal surface. Some degree of mild 
Type of Survival 
Previous Surgery Transplant (rna) 
SB resection, jejunostomy LSB 30 
SB resection LSB 26 
SB resection LSB 14 
Total enterocolectomy LSB .7 
SB + right colectomy, duodenos- LSB 17 
tomy 
SB resection LSB 14 
None SB 13 
SB resection SB 10 
SB resection SB 10 
SB resection LSB 2.5 
SB resection LSB 6 
mucosal edema can be seen at this stage. Phase 3 
begins at this time. 
Although minimal amounts of enteral formulas can 
be infused through the jejunostomy before phase 3, 
progress in weaning of TPN solutions is not accom-
plished until after phase 3 has begun. Nutritional 
management during this time of adaptation has 
consisted of balanced TPN solutions using dextrose, 
crystalline amino acids, and fat emulsions sufficient to 
provide 100 kcallkg/ d administered via the central 
vein. Enteral feedings are begun using standard 
formulas (Tolerex [Sandoz Nutrition, Minneapolis 
Falls, MN], Peptamen [Clintec Nutrition Co, Deer-
field, IL], Compleat-B [Sandoz Nutrition, Minneapo-
lis Falls, MND and advanced as tolerated. Elemental 
formulas have not been well tolerated, and our pres-
ent standard is the use of dipeptide formulas such as 
Peptamen. Continuous feedings are provided by a 
nasogastric or nasoduodenal tubes, gastrostomy tubes 
(with extension tube past the pylorus), or jejunostomy 
tube (into the transplanted bowel). Daily stomal 
outputs are measured for volume, pH, presence of re-
ducing substances, and quantitative bacterial cultures. 
Weight at operation and at latest follow-up as well 
as the length of time required for complete adapta-
tion to enteral feedings (independence from TPN) 
are measured. Changes in height are assessed in 
patients less than 18 years of age. Steady weight gain 
on enteral feeding alone was a major criterion for 
hospital discharge. Significant laboratory data in-
clude a total serum protein level, albumin level, 
transferrin level, and vitamin levels. 
All surviving patients are presently offTPN. Recipi-
ents of liver/small bowel grafts usually require a 
mean of 80 days to become independent of TPN, 
whereas the recipients of small bowel grafts are 
weaned from TPN at approximately 30 days posttrans-
plant. Because children have either not learned to eat 
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Fig 6. (AI Endoscopic photograph displaying exfoliation or mucosa caused by rejection in a stiff aperistaltic intestine. (8) Photomicrograph or 
transplanted intestinal mucosa showing evidence or severe rejection . 
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or have acquired an aversion to food, enteral supple-
mentation is required. Only one child is presently 
maintained on oral intake alone. 
Functional studies included the absorption of D-
xylose, and FK-506 as well as fecal fat excretion. 
Abnormalities in absorption, increased stomal out-
put, or dysmotility (rapid or slow transit) prompted 
aggressive immunologic workup. Satisfactory absorp-
tion curves of D-xylose were documented for all 
patients at some point during the postoperative 
course. Peak values ranged from 15 to 20 ng/dL. 
Results improved with time as the transplanted bowel 
recovered normal motility and enteral feedings were 
advanced (Fig 7A). Abnormal results occurred dur-
ing episodes of rejection (both acute and chronic) and 
reflected both absorptive dysfunction as well as dysmo-
tility and hypersecretion that may accompany r~jec­
tion (Fig 7B). 
The excretion of fat in the stool was abnormal in 
almost all patients and tended to be more so in the 
early postoperative course. Fat absorption has im-
proved with time and has normalized in two patients. 
No child has presented clinical steatorrhea; however, 
one adult small bowel transplant recipient with chronic 
rejection and pancreatitis had significant steatorrhea. 
One child with significant fat excretion in the stool 
had consistent bacterial overgrowth. 
Oral FK-506 was initiated at 7 to 14 days posttrans-
plant and usually overlapped with IV FK-506. Ad-
equate absorption was reflected by maintenance of 
satisfactory blood trough levels of IV therapy, which 
occurred between 7 and 46 days postoperatively 
(mean, 27.9 days) in the liver/small bowel recipients 
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and between 19 and 44 days (mean, 2S.2 days) in the 
small bowel only recipients. 
Total protein and albumin levels have improved 
and have been maintained in all children postopera-
tively. The degree of improvement and maintenance 
has been similar for recipients of an isolated small 
bowel and liver/small bowel grafts. 
Weight has increased steadily in all children, with 
percentile increments of 2% to 10% as compared 
with pretransplant weight (Fig SA). More impor-
tantly, growth (a predictable attribute of health in 
children) has also occurred at a satisfactory rate. 
Normal growth rates have been observed for all 
children24 (Fig SB). 
Stomal outputs tended to be high during the initial 
postoperative period. Any change in volume (either 
more or less) prompted an aggressive search for 
rejection. Bacterial overgrowth in the presence of 
high stomal output was treated with oral antibiotics; 
however its relevance is still under study. 
Paregoric, loperamide, Imodium, pectin, somato-
statin, or oral antibiotics were used as appropriate 
when high stomal outputs occurred. Sodium bicarbon-
ate was added to the formula or given IV if metabolic 
acidosis was present. Initial aversion to food has been 
the rule in most children, and they require a pro-
longed period of adaptation and well-being to learn 
the joy of eating. 
Radiological evaluations performed early after 
transplantation were valuable in assessing the muco-
sal pattern, which was normal in most patients. 
Transit times varied from 30 minutes to 5 hours 
(mean, 2 hours). Some evidence of mucosal edema 
CASE 5 
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Fig 7. (A) D-xylose absorp-
tion curves for patient no. 2, 
showing progressive improve· 
ment up to 732 days posttrans-
plant. (8) Patient no. 5 had initial 
improvement fOllowed by dete-
rioration correlating with severe 
rejection and then the develop-
ment of posttransplant Iympho-
proliferative disease. 
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Fig 8. Weight and height 
changes after small bowel trans-
plantation in eight children. 
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Pre-Transplant 
has been seen in the presence of intestinal graft 
rejection. In cases of severe rejection with exfoliation 
of the mucosa, there was ablation of normal mucosal 
pattern and dysmotility. There were significant abnor-
malities of the native (recipient) proximal gastrointes-
tinal tract, characterized by delayed gastric emptying 
in one child and a severely hypotonic and dilated 
duodenum in another. 
There were three deaths, all recipients of the 
combined liver! small bowel graft. One patient had an 
immunodeficiency pretransplant characterized by low 
levels of immunoglobulin G and M, as well as abnor-
mal T- and B-cell function. Pneumocysystis carinii 
pneumonia was diagnosed in the patient on the 
second postoperative day, and subsequently a leak 
from the proximal intestinal anastomosis was ob-
served. Immunosuppression was reduced drastically. 
Erythema of the abdominal wall developed, and 
multiple skin biopsies did not show graft-versus-host 
disease (GVHD) until the 21st postoperative day, 
when apoptosis was noted. Reinstitution of therapeu-
tic immunosuppression was ineffective, and the pa-
tient died of multisystem organ failure. We attribute 
such severe GVHD to inadequate immunosuppres-
sion in the face of a surgical complication, and an 
inherent immunodeficiency disorder. This complica-
tion has not occurred in any other recipient of an 
intestinal graft. 
One patient suffered from paralysis of the right 
hemidiaphragm secondary to phrenic nerve injury. 
This necessitated prolonged ventilatory support and 
Post-Transplant Pre-Transplant Post-Transplant 
tracheostomy. He later experienced multiple epi-
sodes of rejection that were treated with steroid 
boluses, azathioprine, and an increase in baseline 
immunosuppression (FK-506 and steroids). The pa-
tient had pleomorphic lymphoproliferative disease of 
the intestinal allograft, and he died of sepsis and liver 
failure 13 months after transplantation. Another 
patient had a leak from the choledochojejunostomy, 
with sepsis and subsequently severe rejection with 
mucosal sloughing of the intestinal allograft. He died 
of sepsis 72 days after transplantation. 
In this population there was a high incidence of 
infectious complications, which included bacterial, 
fungal, and viral organisms. Translocation of organ-
isms has occurred in the early postoperative course 
and can be an early indicator of small bowel graft 
rejection. This translocation has included both bacte-
rial (Enterococcus, Staphylococcus aureus) and fungal 
agents (Candida albicans). Viral infections included 
CMV, adenovirus, and EBV.25 Posttransplant lympho-
proliferative disease (PTLD) occurred in two pa-
tients, both recipients of liver/small bowel grafts. 
Both patients had multifocal disease and were treated 
with IV acyclovir and withholding of immunosuppres-
sion. One patient died of this complication and was 
described above. The other child survived the PTLD 
and later presented rejection of allograft. This was 
treated successfully with steroids and reinstitution of 
FK-506 immunosuppression. The patient is alive & 
well, and was off TPN 9 months after successful 
treatment (16 months after transplantation). 
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